Trump claims Huawei issue could be resolved in US-China trade deal
Category: #headlines  By Nikita Chaurasia  Date: 2019-05-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Trump claims Huawei issue could be resolved in US-China trade deal
  • The Trump government had effectively banned American companies from conducting business with the Chinese telecommunications equipment company.
  • The President claimed that the complaints against Huawei might possibly by resolved in the U.S.-China trade deal.

U.S President Donald Trump has reportedly claimed that all the complaints brought against Chinese telecommunications equipment company, Huawei Technologies Co. Ltd. (Huawei) could be resolved in the US-China trade deal’s framework.

Reports cite, the Trump government had effectively banned American companies from conducting business with the Chinese telecommunications equipment giant, alleging that the firm is connected to the Beijing government, making it a national security concern.

According to a BBC report, the ongoing trade war between the U.S and China has been escalating in recent weeks through tariff hikes as well as through threats of additional actions. Huawei found itself in the middle of the trade war when Washington put it in a trade blacklist. While the U.S argues that the company is a security risk, China is accusing it of bullying the firm.

Meanwhile, President Trump in his remarks at White House claimed that the firm is very dangerous, citing the things they have done, particularly from the military standpoint and the security standpoint. Trump further added that if the U.S. makes a trade deal with China, Huawei could possibly be included in it in some way or the other.

Recently, Mike Pompeo, the U.S. Secretary of State reportedly accused Huawei CEO, Ren Zhengfei of lying about the firm’s lack of ties with the Chinese government. Pompeo believes that more American firms would stop conducting business with Huawei adding that the White House is working alongside the State Department to ensure all American firms understand the risks of working with Huawei.

Apart from U.S. companies, many international tech firms are also giving heed to Trump administration’s warnings with Panasonic Corp halting some Huawei component shipments and UK-based chip designer ARM also following suit.

While Huawei has been denying Trump administration’s allegations, a conclusion would only be reached in the upcoming US-China trade talks.

Source Credit:

https://uk.reuters.com/article/us-usa-trade-china/trump-says-dangerous-huawei-could-be-included-in-u-s-china-trade-deal-idUKKCN1ST0PA

https://www.bbc.com/news/business-48392021

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
By Nikita Chaurasia

Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with TnMUC1 (Tn/STn glycoform of mucin 1) CAR-T (chimeric a...

Hyundai and Uber team up to develop all-electric flying taxis
Hyundai and Uber team up to develop all-electric flying taxis
By Nikita Chaurasia

In the midst of technological advancements increasing at a commendable pace, Uber’s flying taxi initiative seems to be edging closer to reality – the reality of establishing flying cars in the near future. The ride-hailing giant has appar...

BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
By Nikita Chaurasia

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical firm leveraging artificial intelligence approaches to advance the next wave of medicines in immuno-oncology and neuroscience, has reportedly announced the initiation of its SERENITY progr...